Year All202420232022202120202019 May 05, 2021 Verve Therapeutics Appoints Industry Leader Sheila Mikhail to its Board of Directors Jan 21, 2021 Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates Jan 19, 2021 Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease Jan 06, 2021 Verve Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Nov 23, 2020 Verve Therapeutics to Present at the Piper Sandler Annual Virtual Healthcare Conference Nov 09, 2020 Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020 Sep 25, 2020 Verve Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit Aug 13, 2020 Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series Jun 27, 2020 Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting Jun 17, 2020 Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
Jan 21, 2021 Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
Jan 19, 2021 Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
Nov 09, 2020 Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020
Aug 13, 2020 Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series
Jun 27, 2020 Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting
Jun 17, 2020 Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
